Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Traws Pharma (TRAW) over the last 14 years, with Q1 2025 value amounting to $226000.0.

  • Traws Pharma's Current Deferred Revenue changed 0.0% to $226000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $226000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $226000.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2025, Traws Pharma's Current Deferred Revenue is $226000.0, which was down 0.0% from $226000.0 recorded in Q4 2024.
  • In the past 5 years, Traws Pharma's Current Deferred Revenue registered a high of $227000.0 during Q2 2024, and its lowest value of $226000.0 during Q1 2021.
  • In the last 5 years, Traws Pharma's Current Deferred Revenue had a median value of $226000.0 in 2021 and averaged $226058.8.
  • In the last 5 years, Traws Pharma's Current Deferred Revenue changed by 0.0% in 2021 and then surged by 44.25% in 2024.
  • Traws Pharma's Current Deferred Revenue (Quarter) stood at $226000.0 in 2021, then changed by 0.0% to $226000.0 in 2022, then changed by 0.0% to $226000.0 in 2023, then changed by 0.0% to $226000.0 in 2024, then changed by 0.0% to $226000.0 in 2025.
  • Its Current Deferred Revenue stands at $226000.0 for Q1 2025, versus $226000.0 for Q4 2024 and $226000.0 for Q3 2024.